Kymera Accelerates KT-621 AD Trial Enrollment by Six Months, Data by Year-End 2026
KYMR•Kymera completed enrollment in its Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis six months early, enabling topline data by year-end 2026. It plans to initiate Phase 3 trials by mid-2027 and expects Phase 2b asthma data in late 2027.
1. Enrollment Completion and Timeline Acceleration
Kymera completed enrollment of approximately 200 adult and adolescent patients in the BROADEN2 Phase 2b trial of KT-621 for moderate to severe atopic dermatitis six months ahead of schedule, advancing topline data readout to year-end 2026.
2. BROADEN2 Trial Design and Endpoints
The randomized, double-blind, placebo-controlled study evaluates three KT-621 doses over 16 weeks, with the primary endpoint measuring percent change in Eczema Area and Severity Index at Week 16 and secondary assessments of safety, efficacy, and quality of life.
3. Phase 3 and Asthma Study Plans
Subject to regulatory discussions, Kymera targets initiating Phase 3 trials in atopic dermatitis by mid-2027, while its BREADTH Phase 2b eosinophilic asthma trial continues, with data expected in late 2027.
4. Broader Pipeline and Regulatory Status
KT-621 holds Fast Track designations for atopic dermatitis and eosinophilic asthma, highlighting its potential as the first oral STAT6 degrader and reinforcing Kymera’s targeted protein degradation strategy across multiple type 2 inflammatory diseases.
